Taysha Gene Therapies (TSHA) Competitors $2.67 +0.06 (+2.30%) Closing price 06/11/2025 04:00 PM EasternExtended Trading$2.67 0.00 (0.00%) As of 03:59 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TSHA vs. AMRX, MIRM, ARWR, NAMS, RXRX, KNSA, VCEL, GMTX, DNLI, and CGONShould you be buying Taysha Gene Therapies stock or one of its competitors? The main competitors of Taysha Gene Therapies include Amneal Pharmaceuticals (AMRX), Mirum Pharmaceuticals (MIRM), Arrowhead Pharmaceuticals (ARWR), NewAmsterdam Pharma (NAMS), Recursion Pharmaceuticals (RXRX), Kiniksa Pharmaceuticals (KNSA), Vericel (VCEL), Gemini Therapeutics (GMTX), Denali Therapeutics (DNLI), and CG Oncology (CGON). These companies are all part of the "pharmaceutical products" industry. Taysha Gene Therapies vs. Its Competitors Amneal Pharmaceuticals Mirum Pharmaceuticals Arrowhead Pharmaceuticals NewAmsterdam Pharma Recursion Pharmaceuticals Kiniksa Pharmaceuticals Vericel Gemini Therapeutics Denali Therapeutics CG Oncology Taysha Gene Therapies (NASDAQ:TSHA) and Amneal Pharmaceuticals (NASDAQ:AMRX) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, dividends, profitability, community ranking, risk and valuation. Do analysts recommend TSHA or AMRX? Taysha Gene Therapies currently has a consensus price target of $7.57, indicating a potential upside of 183.57%. Amneal Pharmaceuticals has a consensus price target of $11.60, indicating a potential upside of 49.10%. Given Taysha Gene Therapies' higher possible upside, equities analysts clearly believe Taysha Gene Therapies is more favorable than Amneal Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Taysha Gene Therapies 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00Amneal Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community believe in TSHA or AMRX? Taysha Gene Therapies received 96 more outperform votes than Amneal Pharmaceuticals when rated by MarketBeat users. However, 95.45% of users gave Amneal Pharmaceuticals an outperform vote while only 79.05% of users gave Taysha Gene Therapies an outperform vote. CompanyUnderperformOutperformTaysha Gene TherapiesOutperform Votes11779.05% Underperform Votes3120.95% Amneal PharmaceuticalsOutperform Votes2195.45% Underperform Votes14.55% Does the media favor TSHA or AMRX? In the previous week, Taysha Gene Therapies had 6 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 15 mentions for Taysha Gene Therapies and 9 mentions for Amneal Pharmaceuticals. Taysha Gene Therapies' average media sentiment score of 0.78 beat Amneal Pharmaceuticals' score of 0.55 indicating that Taysha Gene Therapies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Taysha Gene Therapies 4 Very Positive mention(s) 4 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amneal Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders hold more shares of TSHA or AMRX? 77.7% of Taysha Gene Therapies shares are held by institutional investors. Comparatively, 31.8% of Amneal Pharmaceuticals shares are held by institutional investors. 2.7% of Taysha Gene Therapies shares are held by company insiders. Comparatively, 26.6% of Amneal Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has more volatility & risk, TSHA or AMRX? Taysha Gene Therapies has a beta of 1.04, meaning that its share price is 4% more volatile than the S&P 500. Comparatively, Amneal Pharmaceuticals has a beta of 1.05, meaning that its share price is 5% more volatile than the S&P 500. Is TSHA or AMRX more profitable? Amneal Pharmaceuticals has a net margin of -6.88% compared to Taysha Gene Therapies' net margin of -229.67%. Taysha Gene Therapies' return on equity of -106.36% beat Amneal Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Taysha Gene Therapies-229.67% -106.36% -49.16% Amneal Pharmaceuticals -6.88%-346.26%4.85% Which has better valuation & earnings, TSHA or AMRX? Amneal Pharmaceuticals has higher revenue and earnings than Taysha Gene Therapies. Amneal Pharmaceuticals is trading at a lower price-to-earnings ratio than Taysha Gene Therapies, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTaysha Gene Therapies$7.22M79.34-$111.57M-$0.34-7.85Amneal Pharmaceuticals$2.83B0.86-$83.99M-$0.04-194.50 SummaryTaysha Gene Therapies beats Amneal Pharmaceuticals on 9 of the 17 factors compared between the two stocks. Get Taysha Gene Therapies News Delivered to You Automatically Sign up to receive the latest news and ratings for TSHA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TSHA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TSHA vs. The Competition Export to ExcelMetricTaysha Gene TherapiesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$573.15M$3.09B$5.57B$8.62BDividend YieldN/A1.58%5.28%4.18%P/E Ratio4.2433.3227.1720.06Price / Sales79.34469.84410.88157.10Price / CashN/A168.6838.2534.64Price / Book6.683.457.094.70Net Income-$111.57M-$72.35M$3.23B$247.88M7 Day Performance-7.29%6.23%2.91%2.66%1 Month Performance15.09%16.53%9.09%6.40%1 Year Performance-31.71%-16.90%31.75%14.07% Taysha Gene Therapies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TSHATaysha Gene Therapies3.8464 of 5 stars$2.67+2.3%$7.57+183.6%-28.8%$573.15M$7.22M4.24180Analyst ForecastAnalyst RevisionHigh Trading VolumeAMRXAmneal Pharmaceuticals3.7149 of 5 stars$7.61-0.1%$11.60+52.4%+10.7%$2.39B$2.83B-11.197,600Positive NewsMIRMMirum Pharmaceuticals3.8483 of 5 stars$47.05+1.4%$60.73+29.1%+85.0%$2.33B$379.25M-23.29140Analyst RevisionARWRArrowhead Pharmaceuticals3.6102 of 5 stars$16.57-1.4%$43.71+163.8%-32.1%$2.29B$545.21M-3.21400Analyst RevisionNAMSNewAmsterdam Pharma2.9856 of 5 stars$20.16+0.1%$42.86+112.6%+3.2%$2.26B$47.14M-10.724Trending NewsAnalyst ForecastAnalyst RevisionRXRXRecursion Pharmaceuticals1.9245 of 5 stars$5.37-2.2%$7.60+41.5%-37.1%$2.23B$59.82M-3.51400Trending NewsGap UpHigh Trading VolumeKNSAKiniksa Pharmaceuticals3.2478 of 5 stars$30.33+0.3%$38.80+27.9%+61.1%$2.21B$481.17M-216.63220Trending NewsInsider TradeVCELVericel2.67 of 5 stars$43.82+1.2%$61.14+39.5%+2.0%$2.21B$238.54M730.46300Positive NewsGMTXGemini TherapeuticsN/A$50.02+4.2%N/A+33.6%$2.17BN/A-50.0230DNLIDenali Therapeutics4.3524 of 5 stars$14.65-0.3%$33.71+130.1%-29.7%$2.13B$330.53M-5.31430Positive NewsAnalyst RevisionCGONCG Oncology2.4986 of 5 stars$27.00+0.3%$58.22+115.6%-25.6%$2.06B$662K-17.8861Positive NewsAnalyst Revision Related Companies and Tools Related Companies AMRX Alternatives MIRM Alternatives ARWR Alternatives NAMS Alternatives RXRX Alternatives KNSA Alternatives VCEL Alternatives GMTX Alternatives DNLI Alternatives CGON Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TSHA) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump Makes Major Crypto AnnouncementPay close attention to what I'm about to share… Most investors think Trump's pro-crypto policies will lift ...Crypto 101 Media | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredMarch 16th -- America’s most important day?50-Year Legend: Here's The Day Stocks Likely Crash Legendary quant analyst Marc Chaikin says in 50 years on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Taysha Gene Therapies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Taysha Gene Therapies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TSHA Stock Free TSHA Stock Alerts